DK2498626T3 - Næringsmiddelsammensætning til fremme af tarmmikroflorabalance og sundhed - Google Patents

Næringsmiddelsammensætning til fremme af tarmmikroflorabalance og sundhed Download PDF

Info

Publication number
DK2498626T3
DK2498626T3 DK10779417.4T DK10779417T DK2498626T3 DK 2498626 T3 DK2498626 T3 DK 2498626T3 DK 10779417 T DK10779417 T DK 10779417T DK 2498626 T3 DK2498626 T3 DK 2498626T3
Authority
DK
Denmark
Prior art keywords
food composition
colon
fos
fiber
inulin
Prior art date
Application number
DK10779417.4T
Other languages
English (en)
Inventor
Zamzam Fariba Roughead
Jalil Benyacoub
Claudia Roessle
Jennifer Rae Mager
Julie Ann Swanson
Norman Alan Greenberg
Douglas Richard Bolster
Rodenas Clara Lucia Garcia
Florence Rochat
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567734&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2498626(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Application granted granted Critical
Publication of DK2498626T3 publication Critical patent/DK2498626T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/25—Exudates, e.g. gum arabic, gum acacia, gum karaya or tragacanth
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pediatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)

Claims (23)

1. Næringsmiddelsammensætning til administration til et individ, omfattende: en opløselig fiber omfattende et fructo-oligosaccharid (FOS) i en mængde fra 35 til 44 vægtprocent; et polysaccharid, hvor polysaccharidet er gummi arabicum ("AG") og er ikke delvist hydrolyseret guargummi (PHGG) og er til stede i en mængde fra 38% til ca. 50 vægtprocent; og inulin i en mængde fra 12 til 24 vægtprocent; hvor FOS og polysaccharid er til stede i et vægtforhold fra 62:38 til 38:62; of FOS og inulin er til stede i et vægtforhold fra 82:18 til 58:42.
2. Næringsmiddelsammensætning ifølge krav 1, hvor FOS og polysaccharid er til stede i et vægtforhold fra 55:45 til 45:55, eller hvor FOS og inulin er til stede i et vægtforhold fra 76:24 til 64:36.
3. Næringsmiddelsammensætning ifølge krav 1, hvor polysaccharidet er arabinogalactan og FOS er til stede i en mængde mellem 1,5-5,5 g/L, arabinogalactan er til stede i en mængde på 2,5-5,5 g/L og inulin er til stede i en mængde på 5-2,5 g/L.
4. Næringsmiddelsammensætning ifølge krav 3, yderligere omfattende op til 10 g/L PFIGG.
5. Næringsmiddelsammensætning ifølge krav 1, yderligere omfattende mindst en uopløselig fiber i en mængde der er effektiv til at forbedre fordøjelsesfunktion hos individet, hvor den mindst ene uopløselig fiber er en sojafiber, en ærtebælgfiber eller en kombination deraf.
6. Næringsmiddelsammensætning ifølge krav 5, hvor den opløselige fiber og uopløselige fiber er til stede i et forhold på mellem 1,5:1 og 1:1,5, og FOS og AG er til stede i en total mængde på mellem 2,5-3,5 g/L, inulinet er til stede i en mængde fra mellem 1,25-1,75 g/L, og sojafiberen og ærtebælgfiberen hver er til stede i en mængde fra mellem 3.25-4.25 g/L.
7. Næringsmiddelsammensætning ifølge krav 6, hvor den opløselige fiber og uopløselige fiber er til stede i et forhold på henholdsvis 1,25:1 til 1:1,25.
8. Næringsmiddelsammensætning ifølge krav 1 yderligere omfattende mindst én af: antioxidanter, fiskeolier, DHA, EPA, vitaminer, mineraler, plantenæringsstoffer, protein, fedt, probiotika, og kombinationer deraf.
9. Næringsmiddelsammensætning ifølge et hvilket som helst af kravene 1 til 8 til anvendelse til fremmelse af tarmmikroflorabalance og -sundhed.
10. Næringsmiddelsammensætning ifølge krav 9, hvor fremmeisen af tarmmikroflorabalancen og -sundheden er forbedret patienttolerance til forskellige medicinske behandlinger der fører til fordøjelseskanallidelser, sådanne behandlinger omfatte stråleterapi, kemoterapi, fordøjelseskanalkirurgi, anæstesi, administrationen af antibiotika, analgetika, lægemidler, eller behandlinger for diarré.
11. Næringsmiddelsammensætning ifølge krav 9, hvor fremmeisen af tarmmikroflorabalancen og -sundheden er at fremkalde systemiske nyttevirkninger, såsom bedre vækstindhentning hos børn.
12. Næringsmiddelsammensætning ifølge krav 9, hvor fremmeisen af tarmmikroflorabalancen og -sundheden er nedsættelse af hospitalsindlæggelsestid for patienter mens det gør det muligt for sådanne patienter at opnå acceptable ernæringsniveauer og fødeindtagelsesmål med større tolerance for sådanne formuleringer til sådan forøget compliance med fødeindtagelseskrav, og reducerede komplikationer.
13. Næringsmiddelsammensætning ifølge krav 12, hvor de reducerede komplikationer er valgt fra gruppen bestående af diarré, forstoppelse, gastroøsofageal reflux, regurgitation, opkastning, og kombinationer deraf.
14. Næringsmiddelsammensætning ifølge krav 9, hvor fremmeisen af tarmmikroflorabalancen og -sundheden er stimulering af et individs immunsystem.
15. Næringsmiddelsammensætning ifølge krav 14, hvor det stimulerede immunsystem omfatter: i) forbedret GALT-funktion eller ii) forøgede slgA-niveauer og tilvejebringelse af afbalanceret Thl/Th2.
16. Næringsmiddelsammensætning ifølge krav 9, hvor fremmeisen af tarmmikroflorabalancen og -sundheden er forbedret organtransplantationstolerance, eller næringsmiddelsammensætningen bibringer specifikke koloniseringer der tilvejebringer unik opregulering.
17. Næringsmiddelsammensætning ifølge krav 16, hvor opreguleringen fører til: i) reduceret inflammatorisk cytokin der fører til reduceret fedtfri kropsmasse eller, ii) reduceret insulinfrigivelse gennem GLP-1 og GLP-2 eller, iii) reduceret Thl/Th2-uligevægt.
18. Næringsmiddelsammensætning ifølge krav 9 hvor fremmeisen af tarmmi kroflorabalancen og -sundheden er: i) forbedret knoglevækst eller forebyggelse af knoglenedbrydning i en patient med behov derfor, til at forbedre knoglemobilitet og -funktion til at forbedre knoglevækst eller forebygge knoglenedbrydning, eller ii) er forøgelse af absorption af vitaminer, mineraler, næringsstoffer og kombinationer deraf, i et individs tynd- og tyktarm, eller iii) modulere hormoner produceret af fordøjelseskanalen eller reguleret af fordøjelseskanalen, hvor moduleringshormoner er mindst én af: inflammatoriske hormoner er reduceret hos individet; følelse af velbehag af individet er forøget; serotonin er forøget som fører til forbedret søvnmønster hos individet; forbedret søvnkvalitet hos individet; normalisering af appetit; reduktion af depression; forbedret kognition, reduceret Thl/Th2-uligevægt som fører til en reduceret hyppighed af astma; en reduktion i ørebetændelsesmedier, eller iv) forøget butyrat-produktion i en patients tyktarm, idet fremgangsmåden omfatter administration af en effektiv mængde næringsmiddelsammensætning ifølge et hvilket som helst af kravene 1 til 8 til patienten til forøgelse af butyrat-produktion sammenlignet med formuleringerne der ikke indeholder AG til at frembringelse af celleproliferation i tyktarmen og til nedre tyktarms pH til at inhibere væksten af patogene bakterier, eller v) et vedvarende skift over tid i mikrobiota-balancen der begunstiger gavnlige bakterier såsom bifidobakterier, lactobaciller eller bifidobakterier og lactobaciller, eller vi) vedvarende fermentering, lille kæde-fedtsyreproduktion, et skift i saccharolytisk fermentering fra opadgående tyktarm til nedadgående tyktarm der fører til vedvarende carbohydrat-fermentering i den nedadgående tyktarm og nedsat proteinfermentering eller kombinationer deraf, gennem tyktarmen.
19. Næringsmiddelsammensætning ifølge krav 18, hvor forøget absorption af vitaminer, mineraler, næringsstoffer understøtter muskelvækst eller forhindrer muskelmassereduktion eller forbedrer muskelmassegenerhvervelse efter sygdom eller kvæstelse.
20. Næringsmiddelsammensætning ifølge krav 18, hvor butyrat-produktionen fører til mindst én af: anti-inflammatoriske nyttevirkninger der hjælper med at beskytte patientens tarmbarriere; bedre mineralabsorption, normalisering af fordøjelseskanalgennemgangstiden, aftagen i diarré.
21. Næringsmiddelsammensætning ifølge krav 18, hvor et vedvarende skift over tid i mikrobiota-balancen reducerer patogener, især Clostridia.
22. Næringsmiddelsammensætning ifølge krav 21, hvor Clostridia er reduceret i den distale tyktarm.
23. Næringsmiddelsammensætning ifølge krav 18, hvor ved vedvarende fermentering, lille kæde-fedtsyreproduktion, et skift i saccharolytisk fermentering fra opadgående tyktarm til nedadgående tyktarm: i) der er forbedret næringsmiddel-reabsorption, vand-reabsorption, eller elektrolyt-reabsorption, eller kombinationer deraf, eller ii) der er forbedret tarmregularitet, forbedret forstoppelse, forbedret diarré, forbedret irritabelt udtømningssyndrom, forbedret Crohn's sygdom, forbedret ulcerativ colitis eller kombinationer deraf, eller iii) produktion af vigtige kort kæde fedtsyrer, butyrat, proprionat, eller kombinationer deraf, eller iv) der er reduceret pH, et foretrukket substrat for kolonocytter, bedre næringsmiddel-præsentation for kolonocytterne, gennem hele længden af tyktarmen.
DK10779417.4T 2009-11-12 2010-11-11 Næringsmiddelsammensætning til fremme af tarmmikroflorabalance og sundhed DK2498626T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26049509P 2009-11-12 2009-11-12
US26443009P 2009-11-25 2009-11-25
US39480510P 2010-10-20 2010-10-20
PCT/US2010/056321 WO2011060123A1 (en) 2009-11-12 2010-11-11 Nutritional composition for promoting gut microbiota balance and health

Publications (1)

Publication Number Publication Date
DK2498626T3 true DK2498626T3 (da) 2015-07-13

Family

ID=43567734

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10779417.4T DK2498626T3 (da) 2009-11-12 2010-11-11 Næringsmiddelsammensætning til fremme af tarmmikroflorabalance og sundhed

Country Status (14)

Country Link
US (2) US9192179B2 (da)
EP (1) EP2498626B1 (da)
JP (2) JP6006117B2 (da)
CN (2) CN104206946A (da)
AU (1) AU2010319490B2 (da)
BR (1) BR112012011294B1 (da)
CA (1) CA2777941C (da)
DK (1) DK2498626T3 (da)
ES (1) ES2545597T3 (da)
HK (1) HK1172516A1 (da)
IN (1) IN2012DN03632A (da)
MX (1) MX336032B (da)
RU (1) RU2012123959A (da)
WO (1) WO2011060123A1 (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6006117B2 (ja) * 2009-11-12 2016-10-12 ネステク ソシエテ アノニム 腸内微生物叢バランス及び健康を促進するための栄養組成物
WO2012092160A2 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
US10039296B2 (en) 2011-06-20 2018-08-07 H.J. Heinz Company Brands Llc Probiotic compositions and methods
WO2012175639A1 (en) * 2011-06-22 2012-12-27 Universite De Rouen Arabinogalactan proteins for use as an antiparasitic agent
FI126711B (fi) * 2011-10-12 2017-04-13 Gut Guide Oy Serotoniinivajeeseen liittyvän terveysriskin arvioiminen
PL2768312T3 (pl) 2011-10-18 2016-06-30 Nestec Sa Kompozycja do stosowania dla wspomagania zdrowego rozwoju oraz/albo w zapobieganiu oraz/albo w leczeniu chorób kości
TW201318566A (zh) * 2011-11-01 2013-05-16 Jimmy Lu 膳食補充劑組合物及其用於調控血糖之方法
CN110201003A (zh) 2012-02-29 2019-09-06 伊西康内外科公司 微生物区系的组合物及与其相关的方法
ITRM20120084A1 (it) * 2012-03-07 2013-09-08 Aboca Spa Societa Agricola Miscela prebiotica.
WO2014007606A1 (en) 2012-07-05 2014-01-09 N.V. Nutricia Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour
US20150283144A1 (en) * 2012-11-01 2015-10-08 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US20150296851A1 (en) * 2012-11-27 2015-10-22 Shanghai Jiao Tong University Compositions for Balancing Gut Microbiota and the Preparation and the Uses thereof
EP3904502A3 (en) 2013-02-04 2022-02-23 Seres Therapeutics, Inc. Compositions and methods
JP6479685B2 (ja) * 2013-02-04 2019-03-06 セレス セラピューティクス インコーポレイテッド 病原性細菌生育の抑制のための組成物および方法
EP2983662A4 (en) * 2013-03-15 2016-09-21 MicroBiome Therapeutics LLC ACTIVE SOY FIBER
CA2906921A1 (en) 2013-03-15 2014-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
GB201305708D0 (en) * 2013-03-28 2013-05-15 Clasado Inc Novel use
US20160051468A1 (en) * 2013-04-11 2016-02-25 Bright Drinks Inc. Compositions for Prevention and/or Treatment of Gastrointestinal Imbalances in Digestive Disorders
ITMI20131467A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
JP6833514B2 (ja) 2013-11-25 2021-02-24 セレス セラピューティクス インコーポレイテッド 相乗作用のある細菌組成物ならびにその製造及び使用方法
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CA2930348C (en) * 2013-12-20 2023-03-07 Nestec S.A. Nutritional compositions for reducing intestinal pathogens
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
CN104187624B (zh) * 2014-08-07 2016-06-08 逯明福 综合营养粉及其制备方法
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
AU2014407509B2 (en) 2014-09-30 2020-09-03 Kimberly-Clark Worldwide, Inc. Synergistic prebiotic composition
BR112017004118B1 (pt) 2014-09-30 2022-04-12 Kimberly-Clark Worldwide, Inc Trama de papel crepado, produto de papel crepado de múltiplas camadas, e, método de fabricação de uma trama de papel crepado prebiótico
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
CN104432069A (zh) * 2014-12-22 2015-03-25 威海百合生物技术股份有限公司 一种肠胃通畅片
JP6338113B2 (ja) * 2015-03-31 2018-06-06 株式会社東洋新薬 除脂肪体重の増加剤
EP3397960B1 (en) * 2015-12-30 2020-01-29 Société des Produits Nestlé S.A. Method for determining fat free body mass
CA3009427A1 (en) * 2015-12-31 2017-07-06 Nestec S.A. Composition for improving mouthfeel
BR112018015097A2 (pt) * 2016-02-04 2018-12-26 Universiteit Gent composição e reatores
CA3021316A1 (en) 2016-04-20 2017-10-26 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for nucleic acid expression and protein secretion in bacteroides
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
US20200016256A1 (en) * 2016-09-22 2020-01-16 The University Of Chicago Immune response modulation using live biotherapeutics, for conditions such as allergy desensitization
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
AU2017376780A1 (en) 2016-12-15 2019-07-04 Novome Biotechnologies, Inc. Compositions and methods for modulating growth of a genetically modified gut bacterial cell
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
CN108245530A (zh) * 2016-12-28 2018-07-06 兰州奇正生态健康品有限公司 一种具有润肠通便作用的组合物及其制备方法与用途
ES2683014B1 (es) * 2017-03-23 2019-01-16 Cuetara S L Galleta infantil sin azúcares añadidos
WO2018237149A1 (en) 2017-06-21 2018-12-27 Abbott Laboratories METHODS FOR INCREASING THE GROWTH OF BENEFICIAL BACTERIA IN THE GASTROINTESTINAL TRACT
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
IT201700108033A1 (it) * 2017-09-27 2019-03-27 Neilos S R L Composizione per il trattamento della costipazione
IT201700108039A1 (it) 2017-09-27 2019-03-27 Neilos S R L Composizione per il trattamento della costipazione
EP3466276A1 (en) 2017-10-05 2019-04-10 Pharmactive Biotech Products, S.L. Dietary fiber composition for protecting bioactive compounds during the physiological digestion process
EP3704958A4 (en) * 2017-10-31 2021-06-30 Morinaga Milk Industry Co., Ltd. COMPOSITION FOR INCREASING MUSCLE MASS
WO2020127630A1 (en) * 2018-12-19 2020-06-25 Cosucra Groupe Warcoing S.A. Composition comprising chicory root and pea cell wall fiber for treating brachyspira infections
JP2022517237A (ja) 2019-01-18 2022-03-07 シー・ピー・ケルコ・ユー・エス・インコーポレイテツド プレバイオティック組成物およびその使用
WO2020161522A1 (en) * 2019-02-06 2020-08-13 Thd S.P.A. Fiber-based composition
FR3093427B1 (fr) * 2019-03-05 2021-03-05 Mativa Tech Composition pour son utilisation dans la prévention et/ou le traitement de la dysbiose
CN109820865A (zh) * 2019-04-09 2019-05-31 福州大学 低聚木糖和部分水解的瓜尔豆胶复配组合物在预防肥胖及保健品中的应用
JP7321503B2 (ja) * 2019-05-21 2023-08-07 フジ日本精糖株式会社 イヌリンを含む筋肉量減少抑制又は骨密度減少抑制剤
US20220248739A1 (en) 2019-05-29 2022-08-11 N.V. Nutricia Non-digestible oligosaccharides for decreased colonic protein fermentation
CN114377160A (zh) * 2019-07-09 2022-04-22 大连大学 一种落叶松***半乳聚糖组合物的制备方法
CN114341363A (zh) * 2019-08-30 2022-04-12 Hem制药股份有限公司 使用pmas方法的个体化定制型肠道环境改善物质筛选方法
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
CN110679955A (zh) * 2019-11-11 2020-01-14 成都高新区九州华昀医疗美容门诊部有限公司 可改善肠道功能的大鲵活性肽营养组合物
MX2022010647A (es) * 2020-02-27 2022-09-23 Abbott Lab Metodos para mejorar la salud osea.
CN111440841A (zh) * 2020-05-19 2020-07-24 爱礼康生物医药（苏州）有限公司 一种检测膳食纤维对人肠道菌活性影响的方法
EP4231851A1 (en) * 2020-10-21 2023-08-30 Compagnie Gervais Danone Acacia gum for iron induced microbial dysbiosis
JP2022072243A (ja) * 2020-10-29 2022-05-17 帝人株式会社 腸内細菌叢改善用組成物及び腸内腐敗物質産生抑制用組成物
CN112715669A (zh) * 2020-11-24 2021-04-30 本溪木兰花乳业有限责任公司 一种改善便秘的牛奶制品及其制备方法
EP4258904A1 (en) 2020-12-09 2023-10-18 N.V. Nutricia Fibre mixture for young children
EP4119135A1 (fr) * 2021-07-13 2023-01-18 Luxia Scientific Methodes pour reequilibrer la flore intestinale chez les patients souffrant de la maladie de parkinson
EP4370104A1 (en) * 2021-07-16 2024-05-22 Purdue Research Foundation Prebiotic composition and method of use to improve gastrointestinal health in patients with dysbiosis and leaky gut
CN113826892A (zh) * 2021-09-17 2021-12-24 潍坊易北特健康食品有限公司 一种基于肠道微生物调控特定胆汁酸的组合物及制备方法
JPWO2023054625A1 (da) * 2021-09-29 2023-04-06
CN114224925A (zh) * 2021-12-23 2022-03-25 广东格物生物科技有限公司 一种调节肠道健康的益生菌组合物及其制备方法
ES2955633A1 (es) * 2022-04-26 2023-12-04 Servicio Andaluz De Salud Composición para la rehabilitación intestinal
CN115025116B (zh) * 2022-07-13 2023-11-21 纽湃腾（北京）医药科技有限公司 一种显著改善胃食管反流伴肠易激综合征的组合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952314A (en) 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
ES2123903T5 (es) 1995-08-04 2011-02-22 N.V. Nutricia Composición nutritiva conteniendo fibra.
ATE308254T1 (de) 1998-12-15 2005-11-15 Nestle Sa Ballaststoffemischung für enterale zusammensetzung
ATE283697T1 (de) * 2000-03-01 2004-12-15 Nestle Sa Kohlenhydratformulierung (praebiotisches adjuvans) zur steigerung der immunantwort
EP1175905A1 (en) * 2000-07-24 2002-01-30 Societe Des Produits Nestle S.A. Nutritional Composition
US20020044988A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
EP1243273A1 (en) * 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
GB0308104D0 (en) 2003-04-08 2003-05-14 Novartis Nutrition Ag Organic compounds
ITMI20040956A1 (it) 2004-05-12 2004-08-12 Curti Alessandro Composizioni alimentari
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) * 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
CN101299934B (zh) 2005-10-05 2012-08-08 雀巢技术公司 用于促进追赶生长的营养制剂
ITMI20062031A1 (it) 2006-10-23 2008-04-24 Velleja Res Srl Composizioni per la prevenzione del depauperamento della flora intestinale e del danno d'organo successivi a terapia antibiotica
PL2086346T3 (pl) * 2006-11-07 2013-06-28 Procter & Gamble Kompozycje zawierające błonnik oraz sposoby ich wytwarzania i zastosowanie
ITMI20071214A1 (it) * 2007-06-15 2008-12-16 S I I T Srl Servizio Internazi Composizioni a base di componenti prebiotici ed immunogenici per la prevenzione e il trattamento di disturbi gastroenterici da disbiosi e/o alterazioni della normale flora intestinale
US8263164B2 (en) 2007-07-18 2012-09-11 Campina Nederland Holding B.V. Heat stable nutritional beverage and method of preparing it
WO2009075564A1 (en) 2007-12-10 2009-06-18 N.V. Nutricia Paediatric fibre mixture
JP5992654B2 (ja) 2007-12-21 2016-09-14 ニュートリー株式会社 整腸及び／又は便通改善のための組成物
JP6006117B2 (ja) * 2009-11-12 2016-10-12 ネステク ソシエテ アノニム 腸内微生物叢バランス及び健康を促進するための栄養組成物

Also Published As

Publication number Publication date
CN102595934A (zh) 2012-07-18
AU2010319490A1 (en) 2012-05-03
JP6006117B2 (ja) 2016-10-12
CA2777941A1 (en) 2011-05-19
HK1172516A1 (en) 2013-04-26
WO2011060123A1 (en) 2011-05-19
EP2498626A1 (en) 2012-09-19
EP2498626B1 (en) 2015-06-17
BR112012011294A2 (pt) 2015-09-15
US9192179B2 (en) 2015-11-24
CA2777941C (en) 2018-08-14
US10015978B2 (en) 2018-07-10
JP2016166176A (ja) 2016-09-15
CN104206946A (zh) 2014-12-17
US20160100617A1 (en) 2016-04-14
JP6205003B2 (ja) 2017-09-27
AU2010319490B2 (en) 2015-03-19
IN2012DN03632A (da) 2015-06-26
BR112012011294B1 (pt) 2018-03-20
MX336032B (es) 2016-01-07
RU2012123959A (ru) 2013-12-20
US20120269865A1 (en) 2012-10-25
ES2545597T3 (es) 2015-09-14
MX2012004778A (es) 2012-06-01
JP2013510865A (ja) 2013-03-28

Similar Documents

Publication Publication Date Title
US10015978B2 (en) Nutritional composition for promoting gut microbiota balance and health
US11883370B2 (en) Extensional viscosity to promote safe swallowing of food boluses
AU2012351533B2 (en) Extensional viscosity to promote safe swallowing of food boluses
JP2013529193A (ja) 非経口栄養から経腸栄養へ離脱させるための栄養組成物及び方法
US20160192686A1 (en) Cohesive liquid bolus comprising molecules providing visco-elasticity
JP2015527076A (ja) 増粘された乳製品又は乳製品様製品及びそれらを製造するための方法
WO2022248352A1 (en) Stable thickeners and nutritional products to promote safe swallowing for individuals with dysphagia and methods of making and using same